Introduction: The Unmet Need in Transthyretin Amyloidosis
Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, life-threatening disease characterized by the deposition of misfolded transthyretin (TTR) proteins as amyloid fibrils in the myocardium. This leads to restrictive cardiomyopathy, progressive heart failure, and high mortality. Historically, treatment was limited to supportive care and heart transplantation. The landscape shifted with the introduction of TTR stabilizers, but a significant residual risk remained. The advent of RNA interference (RNAi) therapeutics, which target the root cause by ‘silencing’ the production of TTR in the liver, represents a paradigm shift. Vutrisiran, a second-generation RNAi therapeutic, has recently been evaluated in the landmark HELIOS-B trial. This article integrates findings from four pivotal analyses of the HELIOS-B trial to provide a comprehensive overview of vutrisiran’s impact on survival, biomarkers, cardiac structure, and quality of life.
Study Design and Patient Population
HELIOS-B was a Phase 3, double-blind, placebo-controlled trial that randomized 655 patients with ATTR-CM in a 1:1 ratio. Participants received either vutrisiran (25 mg subcutaneously every 12 weeks) or a placebo for up to 36 months. A notable feature of this trial was its reflection of contemporary clinical practice; approximately 40% of patients were receiving tafamidis at baseline. The primary endpoint was a composite of all-cause mortality and recurrent cardiovascular events. Secondary and exploratory endpoints included all-cause mortality through 42 months, changes in cardiac biomarkers (NT-proBNP and Troponin I), echocardiographic measures of structure and function, functional capacity (6-minute walk test), and health status (Kansas City Cardiomyopathy Questionnaire).
Impact on Cardiac Biomarkers: Early Prognostic Indicators
One of the most clinically relevant findings from the HELIOS-B trial concerns the dynamics of N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) and troponin I. Historically, these biomarkers have been independent predictors of mortality in ATTR-CM. The study confirmed that baseline levels are strongly associated with the risk of the primary composite outcome and all-cause mortality (P < 0.0001).
Crucially, vutrisiran treatment led to a rapid and sustained knockdown of circulating TTR, which translated into stabilized or reduced biomarker levels. By month 30, the median change in NT-proBNP was significantly lower in the vutrisiran group (118 pg/mL) compared to the placebo group (753 pg/mL). Similarly, troponin I levels decreased in the vutrisiran arm (-5.8 pg/mL) while increasing in the placebo arm (9.7 pg/mL). The geometric mean fold-change ratio (vutrisiran/placebo) for both biomarkers was 0.68 (P < 0.0001). This suggests that early treatment initiation with vutrisiran can mitigate myocardial stress and injury, providing a biochemical basis for improved clinical outcomes.
Preserving Cardiac Structure and Function: Echocardiographic Insights
Echocardiography remains the cornerstone of monitoring ATTR-CM progression. Secondary analyses of HELIOS-B revealed that vutrisiran exerts a protective effect on the heart’s architecture. At 30 months, patients treated with vutrisiran showed attenuated increases in mean left ventricular (LV) wall thickness and LV mass index compared to placebo. Specifically, the least squares mean difference for LV mass index was -10.6 g/m2 (P < 0.01).
Beyond structure, vutrisiran preserved biventricular systolic and diastolic function. The trial demonstrated an attenuation in the decline of LV ejection fraction (LVEF) and absolute global longitudinal strain (GLS). At 30 months, the difference in LVEF between the vutrisiran and placebo groups was 2.0% (P = 0.02). Furthermore, vutrisiran improved diastolic parameters, such as the E/e' ratio, which is a critical marker of filling pressures. These findings are significant because worsening echocardiographic parameters at 18 months were shown to be independently associated with a higher risk of the primary composite outcome. By slowing the progression of structural remodeling and functional decline, vutrisiran addresses the mechanical drivers of heart failure in ATTR-CM.
Functional Capacity and Quality of Life
For patients living with ATTR-CM, the impact on daily life and physical capacity is paramount. The HELIOS-B trial utilized the 6-minute walk test (6-MWT) and the Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) to quantify these effects. At 30 months, vutrisiran-treated patients were significantly more likely to maintain or improve their functional capacity. For instance, 68.5% of patients in the vutrisiran group maintained their 6-MWT distance (within a 35m decline) compared to 51.6% in the placebo group.
Health status and quality of life (QOL) showed similar trends. A greater proportion of patients receiving vutrisiran experienced maintenance or improvement in KCCQ-OS scores across various clinically meaningful thresholds (>5 and >10 points). These benefits were consistent across prespecified subgroups, including those receiving tafamidis at baseline and those on monotherapy. This indicates that vutrisiran provides robust symptomatic and functional benefits regardless of background therapy, addressing the patient-centered goals of ATTR-CM management.
Expert Commentary: Mechanistic Insights and Clinical Integration
The collective data from HELIOS-B underscores the potency of TTR knockdown. By reducing the production of the precursor protein, vutrisiran effectively limits the substrate available for amyloid formation. This ‘upstream’ intervention appears more effective at halting disease progression than stabilization alone in many patients. The fact that vutrisiran showed benefits on top of tafamidis suggests that further lowering TTR levels or utilizing a different mechanism of action can provide additive clinical value.
From a clinical perspective, the independent prognostic value of early biomarker changes (at month 6) and echocardiographic changes (at month 18) provides clinicians with a framework for monitoring treatment response. If a patient continues to show rising troponin or NT-proBNP despite therapy, it may signal the need for more aggressive intervention or a reassessment of the disease stage. However, the consistent benefit of vutrisiran across various stages of disease (National Amyloidosis Centre stages) supports its use as a foundational therapy.
Conclusion and Future Directions
The HELIOS-B trial provides high-quality evidence that vutrisiran is a highly effective disease-modifying therapy for ATTR-CM. By significantly reducing mortality and cardiovascular events, stabilizing cardiac biomarkers, and preserving both cardiac function and quality of life, vutrisiran addresses the multifaceted challenges of this complex disease. These results support the early initiation of vutrisiran to maximize myocardial preservation.
Future research will likely focus on the long-term safety and efficacy of combination therapies and the potential for RNAi therapeutics to reverse existing amyloid deposits when used in conjunction with emerging ‘amyloid-clearing’ agents. For now, vutrisiran stands as a cornerstone in the modern management of transthyretin amyloidosis with cardiomyopathy.
Funding and Clinical Trial Information
The HELIOS-B trial was funded by Alnylam Pharmaceuticals. ClinicalTrials.gov Identifier: NCT04153149.
References
1. Maurer MS, et al. Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B. J Am Coll Cardiol. 2025;86(6):459-475.
2. Jering KS, et al. Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With Cardiomyopathy. J Am Coll Cardiol. 2025;86(6):444-455.
3. Jering KS, et al. Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial. Nat Med. 2025;31(10):3560-3568.
4. Sheikh FH, et al. Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis With Cardiomyopathy. J Am Coll Cardiol. 2025;85(20):1943-1955.